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ORIGINAL INVESTIGATION
Glucagon-like peptide-1 protects 
against ischemic left ventricular dysfunction 
during hyperglycemia in patients with coronary 
artery disease and type 2 diabetes mellitus
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Abstract 
Background: Enhancement of myocardial glucose uptake may reduce fatty acid oxidation and improve tolerance 
to ischemia. Hyperglycemia, in association with hyperinsulinemia, stimulates this metabolic change but may have 
deleterious effects on left ventricular (LV) function. The incretin hormone, glucagon-like peptide-1 (GLP-1), also has 
favorable cardiovascular effects, and has emerged as an alternative method of altering myocardial substrate utiliza-
tion. In patients with coronary artery disease (CAD), we investigated: (1) the effect of a hyperinsulinemic hyperglyce-
mic clamp (HHC) on myocardial performance during dobutamine stress echocardiography (DSE), and (2) whether an 
infusion of GLP-1(7-36) at the time of HHC protects against ischemic LV dysfunction during DSE in patients with type 
2 diabetes mellitus (T2DM).
Methods: In study 1, twelve patients underwent two DSEs with tissue Doppler imaging (TDI)—one during the 
steady-state phase of a HHC. In study 2, ten patients with T2DM underwent two DSEs with TDI during the steady-state 
phase of a HHC. GLP-1(7-36) was infused intravenously at 1.2 pmol/kg/min during one of the scans. In both studies, 
global LV function was assessed by ejection fraction and mitral annular systolic velocity, and regional wall LV function 
was assessed using peak systolic velocity, strain and strain rate from 12 paired non-apical segments.
Results: In study 1, the HHC (compared with control) increased glucose (13.0 ± 1.9 versus 4.8 ± 0.5 mmol/l, 
p < 0.0001) and insulin (1,212 ± 514 versus 114 ± 47 pmol/l, p = 0.01) concentrations, and reduced FFA levels 
(249 ± 175 versus 1,001 ± 333 μmol/l, p < 0.0001), but had no net effect on either global or regional LV function. In 
study 2, GLP-1 enhanced both global (ejection fraction, 77.5 ± 5.0 versus 71.3 ± 4.3%, p = 0.004) and regional (peak 
systolic strain −18.1 ± 6.6 versus −15.5 ± 5.4%, p < 0.0001) myocardial performance at peak stress and at 30 min 
recovery. These effects were predominantly driven by a reduction in contractile dysfunction in regions subject to 
demand ischemia.
Conclusions: In patients with CAD, hyperinsulinemic hyperglycemia has a neutral effect on LV function during DSE. 
However, GLP-1 at the time of hyperglycemia improves myocardial tolerance to demand ischemia in patients with 
T2DM.
Trial Registration: http://www.isrctn.org. Unique identifier ISRCTN69686930
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Background
Hyperglycemia is common in patients presenting with 
acute coronary syndromes (ACS) and a powerful pre-
dictor of morbidity and mortality [1]. Although it has a 
number of direct detrimental effects on the ischemic 
myocardium [2], hyperglycemia is also representative 
of an acute metabolic stress characterised by high adr-
energic-mediated levels of free fatty acids (FFA), insulin 
resistance and impaired glucose utilization [3]. Attempts 
to modulate these metabolic derangements with insulin-
based strategies have failed to demonstrate consistent 
clinical benefits [4, 5] and are yet to be established in the 
management of patients with ACS [6, 7]. There is there-
fore an ongoing requirement for the development of new 
pharmacological therapies to address this problem.
Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone which regulates glucose metabolism by stimulating 
insulin secretion, suppressing glucagon and promoting 
glucose uptake into muscle and adipose tissue. These 
effects are dependent on the prevailing glucose concen-
tration so that the risk of hypoglycemia is minimized [8]. 
As a result, the need for intensive monitoring and con-
comitant glucose infusions associated with insulin-based 
metabolic strategies is obviated [9]. As well as these 
glucoregulatory effects, GLP-1 also has binding sites in 
the heart, and clinical studies demonstrating the cardio-
protective properties of incretin-modulating agents are 
continuing to emerge [10–16]. GLP-1 therefore appears 
attractive as a potential therapeutic adjunct for metabolic 
manipulation in patients with ischaemic heart disease 
(IHD).
We have previously used a model of hyperinsulinemic 
euglycemic clamping (HEC) during dobutamine stress 
echocardiography (DSE) to demonstrate that alteration 
of the myocardial metabolic environment in patients with 
obstructive coronary artery disease (CAD) can attenuate 
left ventricular (LV) ischemic dysfunction, especially in 
those with insulin resistance [17]. However, the effects 
of hyperinsulinemic hyperglycemia (HH) in this setting 
have not been investigated and remain unclear. This study 
was therefore undertaken to answer two questions relat-
ing to patients with CAD. Firstly, we sought to investigate 
the effects of HH on LV performance during dobutamine 
stress. Secondly, we sought to investigate the effect of 
GLP-1 modulation on myocardial function in the setting 




Patients with obstructive CAD (at least one proximal 
stenosis >70% in at least one epicardial coronary artery) 
and preserved resting LV systolic function were invited to 
participate. All patients had undergone recent coronary 
angiography before enrolment in the study. Exclusion 
criteria included LV ejection fraction (EF) <40% (either 
on echocardiography or LV angiography), regional wall 
motion abnormalities at rest, a history of previous myo-
cardial infarction within the preceding 3  months, con-
duction abnormalities, valvular heart disease, patients 
taking insulin, dipeptidyl peptidase-4 (DPP4) inhibitors 
or GLP-1 receptor agonists, and those with permanent 
pacemakers. The study protocol was approved by the 
local ethics committee (REC number 08/H0304/68), and 
conformed with the guidelines set out in the Declaration 
of Helsinki. All participants gave written informed con-
sent. The trial number was ISRCTN69686930
Study design
Two separate studies were undertaken:
•  Study 1: effects of hyperglycemia on myocardial perfor-
mance during dobutamine stress
Each subject underwent two DSEs, performed approxi-
mately one week apart. One DSE, determined randomly, 
was performed during the steady-state phase of a hyper-
insulinemic hyperglycemic clamp (HHC) and the other 
DSE acted as a control (Fig. 1).
•  Study 2: effects of GLP-1 (7-36) on myocardial perfor-
mance during dobutamine stress in the setting of hyper-
glycemia
Consecutive patients with T2DM underwent DSE 
during the steady-state phase of a HHC on two sepa-
rate occasions, approximately one week apart. One DSE, 
determined randomly, was performed during an intrave-
nous infusion of GLP-1 (7-36) amide (Bachem, Germany) 
at a dose of 1.2 pmol/kg/min, and the other DSE (control 
HHC) during an intravenous infusion of normal saline 
(Fig. 2).
Hyperinsulinemic, hyperglycemic clamp
The HHCs were performed as described previously 
[18]. After patients had fasted overnight, a cannula was 
inserted into a vein in the antecubital fossa for infusion 
of glucose. A second cannula was inserted in the oppo-
site arm, which was arterialized using a heating pad set 
at 50°C. In order to raise the blood glucose concentra-
tion to approximately 13  mmol/L, a bolus injection of 
0.3  mg/kg of 25% glucose was given over the first min-
ute of the clamp. Once the bolus was administered, a 
maintenance infusion of 20% glucose was commenced 
at 5  mg/kg/min (study 1) or 2.5  mg/kg/min (study 2) 
and this rate was kept constant for the first 10  min. 
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Blood glucose levels were sampled every 5 min from the 
opposite cannula and analyzed using the glucose oxi-
dase method (YSI 2300, YSI Life Sciences, Ohio, USA). 
Thereafter, the glucose infusion rate was adjusted accord-
ing to the plasma glucose concentration, aiming to main-
tain it at 13 mmol/L. The clamp was then continued for a 
Fig. 1 Flow chart illustrating the study design and timeline of study 1.
Fig. 2 Flow chart illustrating the study design and timeline of study 2.
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minimum of 45 min. Once steady state was achieved, as 
indicated by three consecutive blood glucose values that 
were within 5% of one another, the subjects underwent 
DSE as described below. After cessation of dobutamine, 
the glucose infusion was continued for 15 min and then 
gradually reduced over the next 30 min to avoid rebound 
hypoglycemia.
Dobutamine stress echocardiography
A standard clinical protocol for DSE was used. Subjects 
attended for both studies after an overnight fast and 
their beta-blocker was withheld for 48  h prior to their 
attendance. Oral hypoglycemic agents were omitted on 
the morning of the study. Dobutamine was administered 
intravenously via the antecubital fossa using an infusion 
pump in incremental doses (10 µg/kg/min initially, then 
increased at 3-min intervals to 20, 30 and 40 µg/kg/min 
if tolerated) and if necessary, up to 2 mg of atropine was 
given to achieve the target heart rate. Subjects underwent 
continuous 12-lead ECG monitoring, with blood pres-
sure being recorded at baseline and at the end of each 
stage of dobutamine. Criteria for stopping the test were 
achievement of target heart rate of (220-age) × 0.85 bpm, 
ischemic ECG changes (>2  mm ST depression), angina, 
systolic blood pressure increase to >240  mmHg or 
decrease to <100 mmHg, and severe arrhythmias. Two-
dimensional echocardiography (Vivid 7, GE Medi-
cal Systems) was performed with the patient in the left 
recumbent position, and images were recorded at rest, 
peak stress and in recovery. Three cardiac cycles of the 
apical 4-, 3-, and 2-chamber views were captured with 
tissue Doppler imaging (TDI). The image sector width 
was kept as narrow as possible to maximize the frame 
rate. All recordings were made in gently held mid-expi-
ration to minimize beat-to-beat variability, and the data 
were stored for subsequent off-line analysis (EchoPac 
Version 11, GE Medical Systems).
In addition to blood glucose sampling, blood samples 
were taken in the fasted state to measure insulin, FFA, 
and GLP-1(7-36) concentrations at baseline, at the steady 
state stage of the HHC immediately prior to commence-
ment of the DSE (pre-DSE), during peak dobutamine 
stress and in the recovery phase at 30 min after cessation 
of dobutamine. The syringes for the collection of GLP-1 
samples were pre-prepared with DPP-4 inhibitor (Milli-
pore) to prevent GLP-1 degradation. Plasma GLP-1 lev-
els were measured using a commercially available assay 
(Meso Scale Discovery, Rockville, MD, USA).
Echocardiographic analysis
The scans were analyzed off-line by a reviewer who 
was blinded to the treatment strategy. Regional wall 
LV motion was assessed using a 12-segment model 
comprising the base and mid level of six regional walls 
(anterior, anterolateral, anteroseptal, inferior, infero-
lateral, and inferoseptal) obtained from the three apical 
views. LV volumes and EF were calculated using the 
Simpson biplane method according to the guidelines of 
the American Society of Echocardiography. Global LV 
function was also assessed by mitral annular systolic 
velocity (MASV) averaged from six sites [19]. Peak sys-
tolic tissue velocity, and strain and strain rates were cal-
culated from tissue Doppler velocity data averaged over 
three consecutive beats (Fig.  3). The timings of aortic 
valve opening and closure were made from the tissue 
Doppler waveform. The MYDISE study demonstrated 
that CAD could be diagnosed accurately and objectively 
from off-line measurements of myocardial velocities 
recorded by tissue Doppler echocardiography during 
dobutamine stress [20]. In particular, strain rate imaging 
has been shown to provide objective evidence of induc-
ible ischemia [21], and may be a superior parameter to 
peak tissue velocity [22].
A diameter stenosis of >70% stenosis on coronary angi-
ography was considered hemodynamically significant. 
Myocardial segments were assigned to the perfusion ter-
ritories of stenosed vessels, considering the left anterior 
descending coronary artery to supply the anterior and 
anteroseptal segments, the right coronary artery (when 
dominant) to supply the inferior and inferoseptal seg-
ments, and the circumflex artery to supply the anterolat-
eral and inferolateral segments.
Statistics
The number of subjects had been calculated on the 
basis of previous work in our laboratory in patients 
with CAD, where EF increased from 70.8  ±  5.0% to 
77.0  ±  4.4% when dobutamine stress was performed 
during an intravenous infusion of GLP-1 (7-36). To 
detect a change in global LVEF of 5% after dobutamine 
stress (standardized effect size of 1), 12 patients were 
required (paired t test, α  =  0.05, β  =  0.10). Interim 
analysis was conducted after the first seven participants 
to make adjustments to the sample size if required and 
therefore avoid patients undergoing DSE unnecessar-
ily. Comparisons were made between HHC and control 
scans (study 1), or GLP-1 HHC and control HHC scans 
(study 2), with each patient acting as their own con-
trol. Continuous and discrete variables are expressed as 
mean ±  standard deviation (SD) and compared by use 
of the paired Student’s t test (and repeated measures 
one-way ANOVA for regional function parameters) or 
the Wilcoxon signed-rank test where appropriate after 
testing for normality of distribution using the Shap-
iro–Wilk test. Categorical data are expressed as num-
bers (percentages) and compared by use of McNemar’s 
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test. Two-tailed tests were used on all occasions, and 
a probability value of <0.05 was considered statisti-
cally significant. Intra- and inter-observer variations 
were calculated using the Bland–Altman method and 
expressed as the coefficient of variation (SD divided by 
the average value of the variable)  ±  the 95% limits of 
agreement.
Results
Study 1: effects of hyperglycemia on myocardial 
performance during dobutamine stress
Study population
Twelve patients were assigned to and completed study 1. 
The clinical characteristics of the subjects are shown in 
Table 1.
Fig. 3 Myocardial velocity profile sampled from the mid inferoseptum with corresponding strain rate and strain curves.
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Dobutamine stress echocardiography
The two DSE were conducted 8.5 ± 3.9 days apart. There 
were no differences in the rate-pressure products at 
baseline, peak stress or recovery between the two scans 
(Table 2). Target heart rate was achieved in 6 (50%) sub-
jects in the control study and 7 (59%) in the HHC study. 
As per the protocol, the dobutamine infusions in the 
remaining subjects were terminated early due to the 
development of angina.
Biochemistry
At baseline, there were no differences in the plasma 
concentrations of glucose (4.8  ±  0.5 [HHC] versus 
4.9 ±  0.6  mmol/l [control], p =  0.55), insulin (55 ±  39 
[HHC] versus 86 ± 76 pmol/l [control], p = 0.18) or FFA 
(380  ±  320 [HHC] versus 429  ±  226umol/L [control], 
p = 0.36) between the HHC and control studies (Fig. 4). 
As intended, glucose concentrations at the steady state 
stage of the clamp (pre-DSE) were significantly higher 
than at baseline in the control study (13.3 ± 1.7 [HHC] 
versus 4.9 ± 0.6 mmol/l [control], p < 0.0001). This was 
associated with elevated insulin (378 ± 174 [HHC] versus 
86 ± 76 pmol/l [control], p = 0.0007) and reduced FFA 
concentrations (77 ± 74 [HHC] versus 429 ± 226umol/l 
[control], p = 0.0003).
At peak stress, the metabolic differences between 
the two visits persisted, with higher glucose (13.0 ± 1.9 
[HHC] versus 4.8 ± 0.5 mmol/l [control], p < 0.0001) and 
insulin (1,212 ± 514 [HHC] versus 114 ± 47 pmol/l [con-
trol], p =  0.01) concentrations, and reduced FFA levels 
(249 ± 175 [HHC] versus 1,001 ± 333 μmol/l [control], 
p  <  0.0001), in the clamp study compared with control. 
In the recovery phase at 30 min after cessation of dobu-
tamine (15  min after cessation of the glucose infusion), 
glucose (8.2 ± 3.4 [HHC] versus 5.2 ± 0.8 mmol/l [con-
trol], p  =  0.005) and insulin (491  ±  240 [HHC] ver-
sus 79  ±  72  pmol/l [control], p  =  0.02) concentrations 
remained higher and FFA concentrations lower (46 ± 40 
[HHC] versus 550  ±  262  μmol/l [control], p  <  0.0001) 
in the HHC study, although the magnitude of the differ-
ences was not as great.
Global LV function
There were no differences in EF between the clamped 
and control studies at any stage (pre-DSE 66.3  ±  4.0 
[HHC] versus 66.0 ± 4.7% [control], p = 0.76; peak stress 
67.4 ± 11.0 [HHC] versus 69.1 ± 8.0% [control], p = 0.32; 
recovery 62.2 ± 4.0 [HHC] versus 63.5 ± 5.9% [control], 
p =  0.40). Assessment of global LV function by MASV 
confirmed these findings. The HHC was not observed to 
have any net effect on this parameter before, during or 
after dobutamine stress (pre-DSE 6.2 ± 1.4 [HHC] versus 
Table 1 Clinical data of participants
Data are presented as mean ± SD or n (%). BSA body surface area, HOMA 
IR homeostasis model assessment of insulin resistance, LAD left anterior 
descending artery, LCx left circumflex artery, RCA right coronary artery, CAD 
coronary artery disease.
Study 1 (n = 12) Study 2 (n = 10)
Clinical characteristics
 Age (year) 64.8 ± 7.0 66.1 ± 4.6
 Male sex 11 (92) 10 (100)
 Type 2 diabetes 0 10 (100)
 Weight (kg) 84 (10) 93 (14)
 BSA (m2) 2.0 ± 0.1 2.2 ± 0.2
 HOMA IR 1.3 ± 0.8 2.7 ± 1.3
 HbA1c, (%) – 7.0 ± 0.7
Coronary disease
 LAD stenosis 8 (67) 6 (60)
 LCx stenosis 4 (33) 2 (20)
 RCA stenosis 4 (33) 7 (70)
 Single vessel CAD 8 (67) 7 (70)
 Two vessel CAD 4 (33) 1 (10)
 Three vessel CAD 0 2 (20)
Anti-anginal medications
 B-blocker 11 (92) 6 (60)
 Calcium channel antagonist 1 (8) 7 (70)
 Long-acting nitrate 8 (67) 3 (30)
 Nicorandil 0 4 (40)
Oral hypoglycemic agents
 Metformin – 4 (40)
 Sulfonylurea – 4 (40)
 Thiazolidinedione – 1 (10)
Table 2 Hemodynamic data during DSE scans in study 1
Peak stress Recovery
Control HHC P Control HHC P
Heart rate (bpm) 129 ± 15 128 ± 17 0.87 81 ± 15 78 ± 11 0.32
Systolic blood pressure (mm Hg) 153 ± 29 156 ± 22 0.79 136 ± 27 137 ± 19 0.86
Diastolic blood pressure (mm Hg) 76 ± 13 78 ± 11 0.86 81 ± 11 82 ± 11 0.90
Rate-pressure product (mm Hg bpm) 19,540 ± 3,719 19,900 ± 3,948 0.95 11,010 ± 2,977 10,730 ± 2,209 0.68
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5.8 ± 1.4 cm/s [control], p = 0.14; peak stress 10.4 ± 2.9 
[HHC] versus 10.3 ± 2.9 cm/s [control], p = 0.68; recov-
ery 6.2  ±  1.4 [HHC] versus 5.8  ±  1.4  cm/s [control], 
p = 0.12) (Fig. 5a).
Regional wall LV function
For the 12 paired non-apical segments, there were no 
differences in peak systolic tissue velocity, peak systolic 
strain or peak systolic strain rate between clamped and 
control studies either before the DSE or at peak stress. 
Similarly, at 30 min recovery, the HHC was not observed 
to have any effect on strain or strain rate, although it was 
associated with a small rise in tissue velocity (Table 3).
Ischemic versus non‑ischemic segments
Regions subtended by an artery with a stenosis >70% on 
coronary angiography were defined as potentially sub-
ject to demand ischemia during DSE. The HHC was not 
Fig. 4 a–c Biochemical data (mean ± SEM) during the DSE scans in study 1 at baseline, pre-DSE, peak stress, and 30-min recovery. **p < 0.05.
Fig. 5 Global LV function assessed by peak systolic mitral annular velocity (mean ± SEM) at baseline, peak stress and 30-minute recovery in study 1 
(a) and study 2 (b). **p < 0.05.
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observed to have any effect on parameters of regional 
wall function in either the ischemic or non-ischemic 
segments at any stage of the study, except for a small 
rise in tissue velocity in the non-ischemic segments 
(Table 4).
Study 2: effects of GLP‑1 (7‑36) on myocardial performance 
during dobutamine stress in the setting of hyperglycemia
Study population
Interim analysis of the first seven patients had shown 
significant results, and therefore the number of sub-
jects required was reduced. Ten patients were randomly 
assigned and completed study 2. The clinical characteris-
tics of the subjects are shown in Table 1.
Dobutamine stress echocardiography
The two DSE were conducted 10.8  ±  7.2  days apart. 
There were no differences in the rate-pressure products 
at baseline, peak stress or recovery between the two 
scans (Table 5). Target heart rate was achieved in 6 (60%) 
subjects in the control HHC study and 5 (50%) in the 
GLP-1 HHC study. As per the protocol, the dobutamine 
infusions in the remaining subjects were terminated early 
due to the development of angina.
Biochemistry
At baseline, there were no differences in the plasma 
concentrations of glucose (6.3 ±  0.7 [GLP-1 HHC] ver-
sus 6.1 ±  0.7  mmol/l [control HHC], p =  0.36), insulin 
(73 ±  50 [GLP-1 HHC] versus 71 ±  36  pmol/l [control 
HHC], p = 0.76), FFA (469 ± 173 [GLP-1 HHC] versus 
478  ±  160umol/L [control HHC], p  =  0.78) or GLP-
1(7-36) (1.8 ± 1.6 [GLP-1 HHC] versus 1.8 ± 1.3 pg/ml 
[control HHC], p = 0.92) between the GLP-1 and control 
studies (Fig. 6).
As intended, the GLP-1 infusion increased the plasma 
concentration of active GLP-1(7-36) amide approxi-
mately 50 times above the levels in control (pre-DSE 
72 ±  28 [GLP-1 HHC] versus 1.1 ±  0.8  pg/ml [control 
HHC], p  =  0.0001; peak stress 74  ±  17 [GLP-1 HHC] 
versus 1.7 ± 1.4 pg/ml [control HHC], p = 0.0001), and 
the HHC elevated plasma glucose concentrations dur-
ing both visits to a similar level (pre DSE 13.0  ±  0.9 
[GLP-1 HHC] versus 13.4 ± 1.3 mmol/l [control HHC], 
p  =  0.20; peak stress 13.3  ±  2.4 [GLP-1 HHC] versus 
13.6 ±  1.7  mmol/l [control HHC], p =  0.07). However, 
endogenous insulin production was greater (pre-DSE 
763  ±  735 [GLP-1 HHC] versus 195  ±  157  pmol/l 
[control HHC], p  =  0.03; peak stress 1,405  ±  634 
Table 3 Regional wall LV function in studies 1 and 2
Study 1 Pre‑DSE Peak stress Recovery
Control HHC P Control HHC P Control HHC P
Vs (cm/s) 4.7 ± 1.7 4.8 ± 1.8 0.10 8.5 ± 3.3 8.6 ± 3.9 0.22 4.1 ± 1.6 4.6 ± 3.1 0.02
Strain (%) −17.1 ± 6.9 −16.9 ± 7.7 0.46 −15.8 ± 7.0 −15.9 ± 6.9 0.62 −14.3 ± 6.9 −15.3 ± 7.0 0.06
Strain rate (s−1) −1.1 ± 0.4 −1.1 ± 0.5 0.66 −1.8 ± 0.9 −1.8 ± 0.8 0.89 −1.0 ± 0.5 −1.0 ± 0.5 0.75
Study 2 Control GLP‑1 P Control GLP‑1 P Control GLP‑1 P
Vs (cm/s) 4.58 ± 1.62 4.56 ± 1.58 0.82 9.33 ± 3.25 9.78 ± 3.21 0.008 4.46 ± 1.48 5.01 ± 1.67 <0.0001
Strain (%) −15.18 ± 5.94 −15.06 ± 5.05 0.77 −15.51 ± 5.39 −18.09 ± 6.58 <0.0001 −14.29 ± 5.35 −16.62 ± 5.71 <0.0001
Strain rate (s−1) −1.04 ± 0.36 −1.06 ± 0.35 0.50 −2.02 ± 0.71 −2.30 ± 0.75 <0.0001 −0.96 ± 0.31 −1.18 ± 0.36 <0.0001
Table 4 Ischemic versus non-ischemic segments in study 1
Ischemic Pre‑DSE Peak stress Recovery
Control HHC P Control HHC P Control HHC P
Vs (cm/s) 4.54 ± 1.7 4.66 ± 1.7 0.14 8.54 ± 3.6 8.61 ± 4.7 0.44 3.94 ± 1.5 4.06 ± 1.9 0.12
Strain (%) −16.73 ± 7.0 −16.68 ± 8.2 0.87 −14.93 ± 7.0 −15.21 ± 7.1 0.49 −14.33 ± 6.9 −14.72 ± 6.8 0.25
Strain rate (s−1) −1.02 ± 0.4 −1.06 ± 0.5 0.44 −1.81 ± 1.0 −1.84 ± 0.8 0.36 −0.99 ± 0.6 −1.02 ± 0.5 0.32
Non‑ischemic Control GLP‑1 P Control GLP‑1 P Control GLP‑1 P
Vs (cm/s) 4.84 ± 1.8 4.95 ± 1.9 0.22 8.44 ± 3.0 8.56 ± 3.1 0.23 4.34 ± 1.7 5.06 ± 3.9 0.03
Strain (%) −17.50 ± 6.8 −17.22 ± 7.2 0.32 −16.72 ± 7.1 −16.74 ± 6.8 0.77 −14.24 ± 7.0 −15.86 ± 7.3 0.06
Strain rate (s−1) −1.12 ± 0.5 −1.10 ± 0.5 0.74 −1.74 ± 0.7 −1.78 ± 0.8 0.29 −1.04 ± 0.5 −1.07 ± 0.5 0.23
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[GLP-1 HHC] versus 864 ±  743  pmol/l [control HHC], 
p  =  0.002) and FFA concentrations lower (pre-DSE 
302 ± 198 [GLP-1 HHC] versus 359 ± 209umol/l [con-
trol HHC], p  =  0.006; peak stress 321  ±  216 [GLP-1 
HHC] versus 568 ± 364umol/l [control HHC], p = 0.03) 
after GLP-1 than in the control studies.
In the recovery phase at 30  min after cessation of 
dobutamine (15  min after cessation of the GLP-1 and 
glucose infusions), the GLP-1(7-36) amide concentra-
tion remained higher than in control (3.2 ±  1.9 [GLP-1 
HHC] versus 1.0 ± 1.0 pg/ml [control HHC], p = 0.03) 
resulting in a lower glucose concentration (10.4  ±  3.2 
[GLP-1 HHC] versus 12.6 ± 2.5 mmol/l [control HHC], 
p  =  0.004). Insulin concentrations remained higher 
(1,218 ±  1,455 [GLP-1 HHC] versus 493 ±  586  pmol/l 
[control HHC], p = 0.05) and FFA concentrations lower 
(106 ± 50 [GLP-1 HHC] versus 230 ± 158μmol/l [con-
trol HHC], p = 0.02) in the GLP-1 study.
Global LV function
There was no difference in resting EF between the GLP-1 
and control studies (pre-DSE 58.1  ±  4.5 [GLP-1 HHC] 
versus 59.3  ±  6.1% [control HHC], p  =  0.41). At peak 
stress, there was a greater increase in LV function after 
GLP-1 infusion during hyperglycemia (77.5 ± 5.0 [GLP-1 
HHC] versus 71.3  ±  4.3% [control HHC], p  =  0.004), 
and this improved performance persisted into recovery 
(59.6  ±  3.6 [GLP-1 HHC] versus 50.1  ±  5.8% [control 
HHC], p  <  0.0001). Assessment of global LV function 
by MASV confirmed these findings. LV function was 
Table 5 Hemodynamic data during DSE scans in study 2
Peak stress Recovery
Control‑HHC GLP‑1‑HHC P Control‑HHC GLP‑1‑HHC P
Heart rate (bpm) 126 ± 13 125 ± 9 0.83 71 ± 11 77 ± 9 0.14
Systolic blood pressure (mm Hg) 200 ± 25 206 ± 25 0.82 152 ± 22 146 ± 29 0.37
Diastolic blood pressure (mm Hg) 84 ± 24 81 ± 18 0.87 83 ± 14 84 ± 24 0.84
Rate-pressure product (mm Hg bpm) 25,177 ± 4,564 26,197 ± 3,883 0.92 10,733 ± 2,227 11,159 ± 2,788 0.54
Fig. 6 a–d Biochemical data (mean ± SEM) during the DSE scans in study 2 at baseline, pre-DSE, peak stress, and 30-min recovery. **p < 0.05.
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similar before both scans (pre-DSE 6.1  ±  0.9 [GLP-1 
HHC] versus 6.1 ±  0.8  cm/s [control HHC], p =  0.93). 
However, after GLP-1 infusion during hyperglycemia, 
myocardial performance was enhanced both at peak 
stress (11.9 ± 2.7 [GLP-1 HHC] versus 11.0 ± 2.9 cm/s 
[control HHC], p = 0.01) and at 30 min after dobutamine 
stress (6.7  ±  0.6 [GLP-1 HHC] versus 6.1  ±  0.7  cm/s 
[control HHC], p = 0.02) (Fig. 5b).
Regional wall LV function
For the 12 paired non-apical segments, there were no 
differences in peak systolic tissue velocity, peak systolic 
strain or peak systolic strain rate between the GLP-1 and 
control studies pre-DSE. However, at peak dobutamine 
stress, all three parameters of regional wall function were 
enhanced after GLP-1 infusion, and these improvements 
persisted into recovery (Tables 3, 6).
Ischemic vs non‑ischemic segments
GLP-1 infusion during hyperglycemia had a greater ben-
eficial effect on ischemic than on non-ischemic segments 
(Table 7).
Reproducibility
We have previously assessed the reproducibility of the 
parameters presented in six randomly selected patients 
for the images recorded at rest, peak stress, and in recov-
ery. The intra- and inter-observer variations for the 
tissue Doppler imaging parameters were, respectively, 
6.12 ± 0.96% and 6.40 ± 0.99% for MASV, 7.22 ± 0.93% 
and 5.80  ±  0.76% for tissue velocity, 11.0  ±  3.56% 
and 12.6  ±  4.04% for strain, and 9.75  ±  0.29% and 
11.6 ± 0.34% for strain rate. For LVEF, the intra-observer 
variation was 5.69 ± 7.00%, and the inter-observer varia-
tion was 6.59 ± 8.18%.
Discussion
In these studies, we have demonstrated two key findings 
in patients with IHD: (1) HH has a neutral effect on LV 
function during dobutamine stress; and (2) in patients 
with T2DM, an intravenous infusion of GLP-1(7-36) 
amide at the time of hyperglycemia enhances myocardial 
performance during dobutamine stress.
Hyperglycemia and the myocardium
It is well recognised that acute hyperglycemia may 
have a direct detrimental effect on ischemic myocar-
dium. Although a large number of potential mecha-
nisms have been postulated, those relevant to demand 
ischemia include increased oxidative stress and reduced 
nitric oxide production [23] leading to a reduction in 
flow-mediated, endothelium-dependent vasodilatation 
[24, 25], and increased production of endothelial vaso-
constrictor prostanoids which impairs the acetylcho-
line-mediated vasodilator response [26]. In contrast, 
hyperinsulinemia is thought to have several beneficial 
Table 6 Repeated measures analysis of  regional wall function (control versus  GLP-1 studies) at  different time points 
in study 2
Pre‑DSE Peak Stress Recovery
Mean  
difference
95% CI of  
difference
P Mean  
difference
95% CI of  
difference
P Mean  
difference
95% CI of  
difference
P
Vs (cm/s) −0.0002 −0.29 to 0.29 >0.99 −0.42 −0.80 to −0.04 0.02 −0.56 −0.86 to −0.26 <0.0001
Strain (%) 0.17 −1.18 to 1.52 >0.99 −2.94 −4.63 to −1.24 <0.0001 −2.25 −3.77 to −0.73 0.0006
Strain rate (s−1) −0.01 −0.09 to 0.07 >0.99 −0.29 −0.49 to −0.08 0.001 −0.23 −0.32 to −0.13 <0.0001
Table 7 Ischemic versus non-ischemic segments in study 2
Ischaemic Pre‑DSE Peak stress Recovery
Control HHC P Control HHC P Control HHC P
Vs (cm/s) 4.69 ± 1.53 4.66 ± 1.48 0.46 8.50 ± 3.07 8.70 ± 2.99 0.03 4.59 ± 1.53 4.90 ± 1.79 <0.0001
Strain (%) −14.84 ± −5.51 −14.91 ± 4.39 0.82 −16.75 ± 5.26 −18.26 ± 7.38 <0.0001 −15.61 ± 5.47 −16.65 ± 5.72 0.006
Strain rate (s−1) −0.99 ± 0.29 −1.00 ± 0.29 0.71 −2.02 ± 0.79 −2.17 ± 0.70 <0.0001 −1.10 ± 0.29 −1.21 ± 0.38 <0.0001
Non‑ischaemic Control GLP‑1 P Control GLP‑1 P Control GLP‑1 P
Vs (cm/s) 4.44 ± 1.73 4.46 ± 1.70 0.81 10.80 ± 3.05 11.06 ± 3.01 0.09 4.92 ± 1.41 5.15 ± 1.52 0.001
Strain (%) −15.43 ± 6.41 −15.23 ± 5.75 0.48 −16.86 ± 5.59 −17.89 ± 5.57 0.007 −15.26 ± 5.27 −16.57 ± 5.79 0.0009
Strain rate (s−1) −1.11 ± 0.41 −1.12 ± 0.39 0.55 −2.32 ± 0.70 −2.45 ± 0.79 0.006 −1.04 ± 0.32 −1.15 ± 0.35 <0.0001
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effects on ischaemic myocardium, including a reduc-
tion in the circulating concentration of FFAs [27], and a 
subsequent shift towards greater myocardial glucose uti-
lization, which improves overall myocardial oxygen effi-
ciency [28].
In our study, the HHC stimulated endogenous insulin 
production and resulted in inhibition of lipolysis with 
an associated reduction in FFA concentration. At peak 
stress, the combination of pancreatic β1-stimulation 
from dobutamine and hyperglycemia led to a marked 
potentiation of insulin release, increasing further the dif-
ferences between insulin and FFA. These metabolic dif-
ferences persisted (but to a lesser degree) in the recovery 
phase at 30 min after cessation of dobutamine. However, 
despite these metabolic alterations, there was no signifi-
cant net effect observed on either global or regional LV 
function during dobutamine stress or in recovery.
These findings are in contrast to the results of our 
previous work where we observed improved myocar-
dial performance in patients with CAD undergoing DSE 
during the steady state stage of a HEC [17]. Whilst both 
clamp techniques would be expected to promote simi-
lar changes in myocardial metabolism (i.e. a transition 
from predominantly FFA oxidation to greater glucose 
utilization), HHC has been shown to reduce myocardial 
perfusion reserve when compared with HEC in both dia-
betic [29] and non-diabetic patients [30]. Therefore, the 
observed differences on LV function between the two 
clamp techniques might be explained by a counterbal-
ance between the favourable effects of hyperinsuline-
mia on myocardial function and the inhibitory effects of 
hyperglycemia on coronary vasodilatation. In contrast 
to this hypothesis, Nielsen et  al. found that short-term 
hyperglycemia (induced by discontinuation of insu-
lin) in patients with T2DM increased LV contractility 
in patients with both normal and reduced EF. However, 
these results are not directly comparable to those of our 
study, which assessed non-insulin requiring diabetics 
using a different protocol to induce hyperglycemia (i.e. 
exogenous glucose clamp with subsequent large increase 
in insulin levels) [31].
Insulin resistance and the myocardium
Insulin resistance refers to the reduced response of glu-
cose uptake to the stimulatory effect of insulin. In the 
myocardium, insulin resistance suppresses oxidation of 
glucose, improves fatty acid metabolism and alters intra-
cellular signalling, leading to numerous impairments of 
excitation–contraction coupling, less efficient energy 
production and increased susceptibility to ischemia/rep-
erfusion injury [32]. Although these changes are common 
in patients with diabetes, they are frequently unrecog-
nised. However, sensitive echocardiographic techniques 
such as TDI and SR imaging allow for earlier detection 
of asymptomatic LV dysfunction in these individuals. 
Compared with healthy age- and sex-matched controls, 
subjects with insulin resistance demonstrate a reduced 
increase in longitudinal SR values during DSE, suggesting 
reduced LV contractile reserve [33]. In patients with dia-
betes, longitudinal strain reserve (defined as the differ-
ence between global longitudinal strain before and after 
dipyridamole infusion) is increased compared to non-
diabetics [34]. Furthermore, patients with T2DM and 
microvascular angina demonstrate reduced early dias-
tolic peak velocities and peak systolic two-dimensional 
strain than healthy age- and sex-matched controls [35].
GLP‑1 and hyperglycemia
To the best of our knowledge, our study is the first to 
investigate the effect of GLP-1 modulation on LV func-
tion during myocardial ischemia in the setting of hyper-
glycemia in patients with T2DM and CAD. In study 2, 
there were no differences in GLP-1 levels or LV function 
between the two scans at baseline. Infusion of GLP-1 
during HHC increased the plasma concentration of 
active GLP-1(7-36) amide approximately 50 times above 
the levels in control, resulting in increased insulin and 
suppressed FFA concentrations. Compared with con-
trol, GLP-1 was associated with improved parameters of 
both global and regional LV performance at peak stress 
and at 30  min recovery. These effects were predomi-
nantly driven by a reduction in contractile dysfunction 
in regions subject to demand ischemia. Glucose levels 
were similarly elevated in both scans, suggesting that the 
favorable cardiovascular effects were due to GLP-1 itself 
and not to euglycemia. Although insulin concentrations 
were higher during the GLP-1 scan, numerous studies 
have demonstrated that incretin-related cardioprotection 
occurs independent of an effect on insulin [14, 16, 36].
Over the last decade, there has been an increasing body 
of evidence highlighting the favorable cardiovascular 
properties of GLP-1 [37–39]. In animal studies that have 
assessed cardiac metabolic alterations, GLP-1 modula-
tion was associated with increased myocardial glucose 
uptake [40, 41], reduced myocardial levels of lactate and 
pyruvate [42], and an increase in the relative oxidation 
of carbohydrate versus fat [41]. GLP-1 may therefore 
confer its cardioprotective effects by inducing a shift 
towards greater myocardial glucose utilization, an adap-
tive response which is known to be more oxygen efficient 
than fatty acid metabolism [43], but which is impaired 
in the context of insulin resistance. In keeping with this 
concept, we found that ischemic segments derive more 
benefit than non-ischemic segments.
Hyperglycaemia is known to be associated with an 
adverse prognosis in patients presenting with ACS [1]. 
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However, attempts to improve outcomes with insulin-
based strategies have proven to be ineffective. Intense 
insulin therapy (to achieve euglycemia) has been associ-
ated with increased mortality and hypoglycemia when 
compared with moderate glucose control [4]. Simi-
larly, glucose-insulin-potassium infusions (which aim 
to achieve high insulin and circulating glucose levels in 
order to increase myocardial glucose uptake and inhibit 
the adverse effects of FFA) have also failed to demon-
strate consistent clinical benefits [5]. The results of our 
study indicate that GLP-1 may offer an important thera-
peutic adjunct as a metabolic agent for cardioprotection 
in patients with T2DM.
Limitations
This study has a number of important limitations. Firstly, 
we have used tissue Doppler-derived indices of myocar-
dial deformation to assess regional LV function, which 
has a number of potential pitfalls compared with two-
dimensional speckle tracking echocardiography (STE). 
These include a high dependence on a favorable angle of 
incidence during image acquisition, an inability to accu-
rately assess apical segments, and potentially high inter-
and intra-observer variations. However, since TDI allows 
for measurements of strain and strain rate with excellent 
temporal resolution, this technique may be advantageous 
to STE at times of higher heart rates (e.g. during dobu-
tamine stress). Secondly, whilst all attempts were made to 
conduct the two DSE scans for each patient in identical 
fashion and to obtain the peak stress images at the same 
degree of dobutamine stress, we cannot exclude the possi-
bility of a degree of variation in the response of individual 
patients to dobutamine on the two separate study days. 
Thirdly, the potential cardioprotective effects of GLP-1 
have been assessed using echocardiographic (and not clin-
ical) endpoints in only a small number of patients. Further 
work, in the form of adequately powered randomized 
controlled trials, is required to ascertain if these favora-
ble cardiovascular effects at the time of demand ischemia 
translate into an improvement in clinical outcomes.
Conclusions
In patients with obstructive CAD, hyperglycemic hyper-
insulinemia has a neutral effect on LV function during 
dobutamine stress. However, an infusion of GLP-1(7-36) 
at the time of hyperglycemia protects the heart against 
demand ischemic LV systolic dysfunction in patients with 
T2DM and IHD.
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